Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

Russell-Jones David; Bode Bruce W.; De Block Christophe; Franek Edward; Heller Simon R.; Mathieu Chantal; Philis-Tsimikas Athena; Rose Ludger; Woo Vincent C.; Osterskov Anne Birk; Graungaard Tina; Bergenstal Richard M.

首页> 外文期刊>Diabetes care >Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

【24h】

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

机译：快速作用的胰岛素Aspart改善了1型糖尿病的基底血管治疗中的血糖控制：26周的多中心，主动控制，治疗目标，随机，并联 - 群试验（发作1）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

OBJECTIVE

机译：客观的

著录项

来源
《Diabetes care》 |2017年第7期|共8页
作者
Russell-Jones David; Bode Bruce W.; De Block Christophe; Franek Edward; Heller Simon R.; Mathieu Chantal; Philis-Tsimikas Athena; Rose Ludger; Woo Vincent C.; Osterskov Anne Birk; Graungaard Tina; Bergenstal Richard M.;
展开▼
作者单位

Royal Surrey Cty Hosp Diabet &

Endocrinol Guildford Surrey England;

Atlanta Diabet Associates Atlanta GA USA;

Antwerp Univ Hosp Dept Endocrinol Diabetol &

Metab Antwerp Belgium;

Polish Acad Sci Mossakowski Med Res Ctr Warsaw Poland;

Univ Sheffield Dept Oncol &

Metab Sheffield S Yorkshire England;

Katholieke Univ Leuven Univ Hosp Leuven Clin &

Expt Endocrinol Leuven Belgium;

Scripps Hlth Scripps Whittier Diabet Inst San Diego CA USA;

Inst Diabet Res Munster Germany;

Univ Manitoba Sect Endocrinol &

Metab Winnipeg MB Canada;

Novo Nordisk AS Soborg Denmark;

Novo Nordisk AS Soborg Denmark;

Int Diabet Ctr Pk Nicollet Minneapolis MN USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词

相似文献

外文文献
中文文献
专利

1. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1) [J] . Russell-Jones David, Bode Bruce W., De Block Christophe, Diabetes care . 2017,第7期

机译：快速作用的胰岛素Aspart改善了1型糖尿病的基底血管治疗中的血糖控制：26周的多中心，主动控制，治疗目标，随机，并联 - 群试验（发作1）
2. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial [J] . Davies M. J., Gross J. L., Ono Y., Diabetes, obesity & metabolism . 2014,第10期

机译：在1型糖尿病中就餐时使用门冬胰岛素作为基础快速推注治疗的一部分药物地格曲松的疗效和安全性：一项为期26周的随机，开放标签，以治疗为目标的非劣效性试验
3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. [J] . Heller S, Koenen C, Bode B Clinical therapeutics . 2009,第10期

机译：在1型糖尿病患者的基础推注方案中，以门冬胰岛素作为进餐时胰岛素对地特胰岛素和甘精胰岛素的比较：52周，多国，随机，开放标签，平行分组，按治疗目标非劣效性试验。
4. Rationale, Design and Preliminary Results of ROMEO (Rethink Organization to Improve Education and Outcomes) A Randomized Controlled Multicenter Trial of Group Care in the Management ofType 1 Diabetes [C] . M. Porta, M. Trent European Association for the Study of Diabetes . 2005

机译：Romeo（重新思考组织改善教育和结果）的基本理由，设计和初步结果，在1型糖尿病的术语中进行了随机对照的组织的多中心试验
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Efficacy and safety of insulin degludec given as part of basal–bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized open-label treat-to-target non-inferiority trial [O] . M J Davies, J L Gross, Y Ono, -1

机译：在1型糖尿病患者中就餐时给予门冬胰岛素作为基础推注治疗的一部分药物以地格曲胰岛素的有效性和安全性为研究对象：一项为期26周的开放性靶向治疗的非劣效性试验
7. Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. [O] . Davies, Melanie J., Gross, J. L., Ono, Y., 2014

机译：在1型糖尿病患者中，就餐时服用门冬胰岛素作为基础推注治疗的一部分，给予地高胰岛素的有效性和安全性：一项为期26周的随机，开放标签，以治疗为目标的非劣效性试验。

Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1)

摘要

著录项

相似文献

相关主题

期刊订阅